---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-100960"
form_type: "8-K"
ticker: null
cik: "0001567514"
company_name: "Intra-Cellular Therapies, Inc."
filed_at: "2024-04-18T23:59:59+00:00"
generated_at: "2026-06-03T18:53:08.871321+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Intra-Cellular Therapies prices $500M public offering of 6.85M shares at $73.00 per share

## Summary
- Gross proceeds of $500M from 6,849,316 shares at $73.00/share; net proceeds ~$472.1M after underwriting discounts and expenses.
- Underwriters granted 30-day option to purchase up to 1,027,397 additional shares on same terms.
- Offering expected to close April 22, 2024; J.P. Morgan, Leerink, BofA, Morgan Stanley, RBC acting as joint book-runners.
- Company is selling all shares; no specific use of proceeds disclosed in the filing.

## SEC filing metadata
- accession: 0001193125-24-100960
- form_type: 8-K
- cik: 0001567514
- company_name: Intra-Cellular Therapies, Inc.
- filed_at: 2024-04-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567514/000119312524100960/0001193125-24-100960-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567514/000119312524100960/d816580d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-100960
- JSON: https://secwatch.observer/filing/0001193125-24-100960.json
- Plain text: https://secwatch.observer/filing/0001193125-24-100960.txt

## Key facts
- Material Agreements
  Intra-Cellular Therapies, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, Leerink Partners LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein valued at approximately $472.1 million (effective 2024-04-17).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: J.P. Morgan Securities LLC, Leerink Partners LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein
  - Value: approximately $472.1 million
  - Effective: 2024-04-17
  source text: On April 17, 2024, Intra-Cellular Therapies, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with J.P. Morgan Securities LLC, Leerink Partners LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and RBC Capital Markets, LLC, as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), relating to an underwritten public offering of 6,849,316 shares (the “ Underwritten Shares ”) of the Company’s common stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567514/000119312524100960/0001193125-24-100960-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.